NewLink Genetics Corporation Культура компании

Mr. Charles J. Link, Jr., M.D. Co-founded NewLink Genetics Corporation in 1999. Mr. Link has been Chief Executive Officer and Chief Scientific Officer of NewLink Genetics Corporation since 2003 and 1999 respectively. Dr. Link has been Chairman and Director of NewLink Genetics Corporation since 1999. Dr. Link serves as a Medical Director of the Bone Marrow Transplantation and Gene Therapy Unit of the Iowa Methodist Medical Center in Des Moines, Iowa and Director of the Gene Therapy Program, Human Gene Therapy Research Institute, also of Des Moines. He serves as a Member of Scientific Advisory Board of OptiMEMS, Inc. He has authored over forty publications. Dr. Link received M.D. with Honours from the Stanford University School of Medicine in Palo Alto, California and B A from the Stanford University.

Mr. Carl W. Langren has been the Vice President of Finance at NewLink Genetics Corporation since January 2011. Mr. Langren served as the Chief Financial Officer of bioprotection systems corporation, from February 2005 to January 2011. He was a principal in capital management solutions. He held positions as chief financial officer of housby mixer group, president of iowa machinery and supply, chief financial officer of equity dynamics, inc., treasurer of dfm corporation and a tax manager with mcgladrey pullen and company. Mr. Langren received a BBA in accounting from the University of Iowa.

Mr. Brian Wiley has been the Chief Commercial Officer of NewLink Genetics Corporation since 2015. Mr. Wiley served as Vice President of Business Development at NewLink Genetics Corporation from January 2013 to 2015. Mr. Wiley served as Senior Director of Marketing and Business Planning at Gloucester Pharmaceuticals, Inc. since August 2005. Mr. Wiley has over ten years of commercial oncology experience. At Millennium Pharmaceuticals, he served as an Associate Director of Market Planning and Development and focused on strategic and pre-market planning for Velcade in emerging indications. Mr. Wiley's previous experience includes a diverse 12 year tenure at Aventis Pharmaceuticals (now Sanofi-Aventis), including management positions in marketing, national accounts & sales. Mr. Wiley received a BS from The Pennsylvania State University and completed graduate level coursework at the University of New Mexico.

Mr. Nicholas N. Vahanian, M.D., has been the President and Chief Medical Officer of NewLink Genetics Corporation since 2009 and 2001 respectively. Mr. Vahanian is on leave of absence. He is the Co-founder NewLink Genetics Corporation and served as Chief Operations Officer since 2003. He has been a Director of NewLink Genetics Corporation Since November 13, 2015. He received B.S. in Biology from Virginia Commonwealth University and M B A from the University of Notre Dame. He attended the St Barthalomew's and Royal London Hospital Medical College.

Mr. Mario Mautino, Ph.D. serves as Senior Vice President of Drug Discovery Module at NewLink Genetics Corporation and has been its ntellectual Property Officer since 2002. Mr. Mautino served as Vice President of Drug Discovery Module at NewLink Genetics Corporation since 2007. Mr. Mautino served as a Senior Scientist at NewLink Genetics from 2001 to 2007. He attended one year of post-doctoral training at the National University of Cordoba and five years of post-doctoral work in human gene therapy at the Clinical Gene Therapy Branch, NIH. Mr. Mautino received his Licenciate in Biological Chemistry in 1990 and his Ph.D. in Molecular Genetics at the University of Cordoba, Argentina in 1995.

Dr. Thomas P. Monath, also known as Tom, M.D., has been the Chief Scientific and Chief Operations Officer at BioProtection Systems Corporation since November 2014. Dr. Monath serves as Chief Operations Officer of Infectious Disease Division and Chief Scientific Officer of NewLink Genetics Corporation. He joined NewLink Genetics in 2014. He serves as an Advisor of Metabiota, Inc. He served as the Chief Medical Officer of HX Diagnostics, Inc. He served as a Venture Partner and Partner at KPCB Pandemic and Bio Defense Fund at Kleiner Perkins Caufield & Byers. He served as Consulting Chief Medical Officer of Mymetics Corporation since August 2012. He served as a Director, Division of Vector-Borne Viral Diseases at U.S. Centers For Disease Control And Prevention (cdc). Dr. Monath has devoted his nearly 30-year career to the fight against infectious disease through his work in the military, corporate, academic and investment sectors. He was a Venture Partner and Partner at Kleiner, Perkins, Caufield & Byers. He served as the Chief Technology Officer of PaxVax Corporation since February 2012. He served as the Chief of the Virology Division at U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). Dr. Monath was an Investment Partner at USAMRIID. He served as the Chief Scientific Officer and Executive Director at Sanofi Pasteur Holding Limited (Acambis Plc) from 1992 to 2006, where Dr. Monath directed research and development on dengue, West Nile, Japanese encephalitis, yellow fever, Clostridium difficile and smallpox vaccines for defense against bioterrorism. He served as Acting Chief Medical Officer of Juvaris BioTherapeutics Inc. He served as Vice President of Research and Medical Affairs at Sanofi Pasteur Biologics Co. since December 1993. Dr. Monath served as a Vice President of Research and Development at Oravax Inc from April 1992 to December 1993. He served as Consultant at Oravax Inc. from October 1991 to March 1992. He served as Director of Division of Vector-Borne Viral Diseases at U.S. Centers for Disease Control, Fort Collins CO, from 1973 and 1988. He served as the Chief of Virology Division in United States Medical Research Institute of Infectious Diseases from 1989 to 1992. Dr. Monath joined Kleiner, Perkins, Caufield & Byers in June 26, 2006 and is a part of the life sciences team and specializes in pandemic and Biodefence investments. He retired from the United States army in 1992 after 24 years in the uniformed services. He serves as a Member of Scientific Advisory Board at GeoVax Labs, Inc. He has been a Director of Rapid Micro Biosystems, Inc. since July 2009. He has been a Director of Juvaris BioTherapeutics, Inc. since January 5, 2007. He serves as a Member of Advisory Board of SmartVet USA Inc. He serves as a Member of Scientific Advisory Board at SutroVax, Inc. He serves as a Director of Acambis Plc. He served as a Director of VaxInnate Corporation since June 2015 until January 09, 2017. He served as a Director of Xcellerex, Inc. He served as a Director of Novavax Inc. from September 2006 to November 2, 2009. He served as a Member of Medical Advisory Board at Symphogen A/S. Dr. Monath is a world-renowned virologist and vaccinologist with over 25 years of experience as a senior biotechnology industry executive, more than 20 years of experience providing service to the Centers for Disease Control and the United States Army with expertise in viral infections and almost 400 publications in the field. Dr. Monath has successfully developed and provided clinical trial oversight of multiple vaccines and has extensive experience and success working with the US Food and Drug Administration. He is on the editorial board of five scientific journals. Dr. Monath received the Nathanial A. Young Award in 1984, the Richard M. Taylor Award in 1996 and the Walter Reed Medal in 2002 from the American Society of Tropical Medicine & Hygiene and was President of that Society from 2004 to 2005. He is an Adjunct Professor at the Harvard School of Public Health. He has published over 40 patents on various products, 380 papers and edited six books on the epidemiology, immunology and pathogenesis of viruses and on vaccine development. In 1992, he retired as a U.S. Army colonel following 24 years in the uniformed services. He trained in Internal Medicine at the Peter Bent Brigham Hospital, Boston. Dr. Monath received an M.D. from Harvard Medical School and a B.A. from Harvard College.

Dr. Eugene P. Kennedy, also known as Gene, MD, FACS has been Chief Medical Officer of NewLink Genetics Corporation since November 14, 2017. Dr. Kennedy served as Vice President for Clinical and Medical Affairs at NewLink Genetics Corporation from February 2014 to November 14, 2017. Dr. Kennedy is responsible for clinical operations related to NewLink's HyperAcute(R) and IDO (indoleamine-(2,3)-dioxygenase) pathway product candidates as well as supporting commercial development strategies. Dr. Kennedy joined NewLink from Thomas Jefferson University in Philadelphia, PA where he served as Associate Professor of Surgery and held leadership positions as Chief of the Section of Pancreaticobiliary Surgery and Co-Director of the Jefferson Pancreas, Biliary and Related Cancers Center. Previously, Dr. Kennedy has held faculty positions at the Johns Hopkins Hospital in Baltimore, MD and the Louisiana State University School of Medicine in New Orleans, LA. He has considerable experience in clinical trial design and implementation, leading both investigator initiated and industry sponsored efforts. He completed a residency and fellowship in Surgery and Surgical Oncology as well as a research fellowship in tumor immunology at the Johns Hopkins Hospital. Dr. Kennedy obtained his undergraduate education at the University of Virginia and received his medical degree from the Medical College of Virginia.

Lisa Miller serves as the Director of Investor Relations of NewLink Genetics. Lisa started at NewLink Genetics in Mar of 2017. Lisa currently resides in the Dallas/Fort Worth Area.

Gabriela Rossi serves as the Vice President Cancer Biology and Immunology of NewLink Genetics. Gabriela started at NewLink Genetics in January of 2002. Gabriela currently resides in the Des Moines, Iowa Area.